CN101909438A - 雷沙吉兰制剂、其制备及用途 - Google Patents

雷沙吉兰制剂、其制备及用途 Download PDF

Info

Publication number
CN101909438A
CN101909438A CN2009801017416A CN200980101741A CN101909438A CN 101909438 A CN101909438 A CN 101909438A CN 2009801017416 A CN2009801017416 A CN 2009801017416A CN 200980101741 A CN200980101741 A CN 200980101741A CN 101909438 A CN101909438 A CN 101909438A
Authority
CN
China
Prior art keywords
pharmaceutical composition
composition according
rasagiline
coating
talc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801017416A
Other languages
English (en)
Chinese (zh)
Inventor
穆罕默德·萨法迪
丹尼特·李驰特
雷切尔·科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN101909438A publication Critical patent/CN101909438A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2009801017416A 2008-01-11 2009-01-09 雷沙吉兰制剂、其制备及用途 Pending CN101909438A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1086008P 2008-01-11 2008-01-11
US61/010,860 2008-01-11
PCT/US2009/000134 WO2009089049A1 (en) 2008-01-11 2009-01-09 Rasagiline formulations, their preparation and use

Publications (1)

Publication Number Publication Date
CN101909438A true CN101909438A (zh) 2010-12-08

Family

ID=40850833

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801017416A Pending CN101909438A (zh) 2008-01-11 2009-01-09 雷沙吉兰制剂、其制备及用途

Country Status (15)

Country Link
US (1) US20090181086A1 (enExample)
EP (1) EP2234478A4 (enExample)
JP (2) JP5583597B2 (enExample)
KR (1) KR20100107028A (enExample)
CN (1) CN101909438A (enExample)
AU (1) AU2009204454B2 (enExample)
BR (1) BRPI0905680A2 (enExample)
CA (1) CA2711817A1 (enExample)
EA (1) EA201070842A1 (enExample)
IL (1) IL206136A0 (enExample)
MX (1) MX2010007601A (enExample)
NZ (1) NZ586025A (enExample)
SG (1) SG187455A1 (enExample)
WO (1) WO2009089049A1 (enExample)
ZA (1) ZA201004086B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
MX2008012781A (es) 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
CN102065687A (zh) * 2008-06-13 2011-05-18 泰华制药工业有限公司 雷沙吉兰用于改善帕金森氏症
NZ589547A (en) * 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
EP2515891A4 (en) 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
CA2806737A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2012323349A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-formyl-propargyl-aminoindan
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
CA2882072A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulations of rasagiline
WO2024098098A1 (en) * 2022-11-07 2024-05-16 Natural MedTech Pty Ltd Tryptamine formulations and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220864A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
SI9420040A (en) * 1993-06-14 1996-08-31 Janssen Pharmaceutica Nv Extended release, film coated tablet of astemizole and pseudoephedrine
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69738275T2 (de) * 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
ES2588780T3 (es) * 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
EA200700158A1 (ru) * 2004-07-26 2007-08-31 Тева Фармасьютикал Индастриес Лтд. Лекарственные формы с ядром таблетки, покрытым энтеросолюбильной оболочкой
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
CN102065687A (zh) * 2008-06-13 2011-05-18 泰华制药工业有限公司 雷沙吉兰用于改善帕金森氏症
NZ589547A (en) * 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
EP2328861A2 (en) * 2008-07-11 2011-06-08 Synthon BV Polymorphs of rasagiline hydrochloride
US20100029987A1 (en) * 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2485722A1 (en) * 2009-10-09 2012-08-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of progressive supranuclear palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
EP2603212A4 (en) * 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
CA2806737A1 (en) * 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
MX2013004598A (es) * 2010-10-26 2013-07-17 Teva Pharma Rasagilina enriquesida con deuterio.
BR112014008552A2 (pt) * 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
EA201490756A1 (ru) * 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз, Лтд. Разагилина цитрамид
AU2012323349A1 (en) * 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-formyl-propargyl-aminoindan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220864A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline

Also Published As

Publication number Publication date
KR20100107028A (ko) 2010-10-04
NZ586025A (en) 2012-08-31
IL206136A0 (en) 2010-11-30
EA201070842A1 (ru) 2011-04-29
AU2009204454A1 (en) 2009-07-16
AU2009204454B2 (en) 2015-02-05
SG187455A1 (en) 2013-02-28
BRPI0905680A2 (pt) 2015-07-07
CA2711817A1 (en) 2009-07-16
JP5583597B2 (ja) 2014-09-03
EP2234478A1 (en) 2010-10-06
JP2011509295A (ja) 2011-03-24
MX2010007601A (es) 2010-08-03
EP2234478A4 (en) 2013-01-23
WO2009089049A1 (en) 2009-07-16
ZA201004086B (en) 2011-08-31
US20090181086A1 (en) 2009-07-16
JP2014237668A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
CN101909438A (zh) 雷沙吉兰制剂、其制备及用途
US8080584B2 (en) Delayed release rasagiline citrate formulation
US20060018957A1 (en) Pharmaceutical dosage forms including rasagiline
AU2013344281B2 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
JP2005512997A (ja) タムスロシン錠
CN101910113A (zh) 左旋多巴控释制剂及其用途
NO20121414A1 (no) Farmasoytiske sammensetninger omfattende hydromorfon og nalokson
US20100040680A1 (en) Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
US20080138411A1 (en) Modified Release Formulations Of Selective Serotonin Re-Uptake Inhibitors
US20140023710A1 (en) Milnacipran formulations
EP2218444A2 (en) Delayed release rasagiline formulation
US20110206769A1 (en) Oral antidepressant formulation with reduced excipient load
HK1150308B (en) Delayed release rasagiline formulation
HK1210042B (en) Pharmaceutical compositions comprising hydromorphone and naloxone
HK1156509A1 (en) Delayed release rasagiline formulation
HK1156509B (en) Delayed release rasagiline formulation
HK1147203A (en) Delayed release rasagiline formulation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101208